Key result
Drug-target Mendelian randomization leverages human genetics to facilitate drug discovery and safety assessment in MASLD.
Why the study?
Despite MASLD being the most prevalent cause of chronic liver disease worldwide, progress in drug development for this condition remains limited.
Answers are grounded in this paper and cite their sources.
Drug-target Mendelian randomisation offers a promising approach leveraging human genetics for discovering and repositioning drug targets in MASLD.
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent cause of chronic liver disease worldwide affecting over one-third of the adult population. Despite the recent evolution of new nomenclature and diagnostic criteria for MASLD, progress in drug development for this condition remains limited. This review highlights the potential of drug-target Mendelian randomisation (MR), a study design that leverages human genetics and genomics, for the discovery, repositioning and safety assessment of drug targets in MASLD. We summarised key aspects of designing and appraising a drug-target MR study, discussing its inherent assumptions and considerations for instrument selection. Furthermore, we presented real-world examples from studies in MASLD which focused on opportunities and challenges in identifying novel drug targets, repositing existing drug targets, informing adjunctive treatments and addressing issues in paediatric MASLD.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2024) studied this question. Drug-target Mendelian randomisation leverages human genetics to facilitate the discovery, repositioning, and safety assessment of drug targets in MASLD.
Synapse has enriched 10 related papers. Consider them for comparative context: